References
- Benagiano G, Bastianelli C, Farris M. Contraception today. Ann. NY Acad. Sci.1092, 1–32 (2006).
- Sartwell PE, Masi AT, Arthes FG et al. Thromboembolism and oral contraceptives: an epidemiologic case/control study. Am. J. Epidemiol.90, 365–380 (1969).
- Rosenberg L, Palmer JR, Sands MI et al. Modern oral contraceptives and cardiovascular diseases. Am. J. Obstet. Gynecol.177, 707–715 (1997).
- WHO. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception: effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet346, 1582–1588 (1995).
- Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case–control study using United States claims data. BMJ340, d2151 (2011).
- Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case–control study based on UK general practice research database. Brit. Med. J.342, d2139 (2011).
- Benagiano G, Bastianelli C, Farris M. Hormonal contraception: present and future. Drugs Today44, 905–923 (2008).
Website
- Drospirenone and risk of venous thromboembolism (VTE) www.medscape.com/viewarticle/743703